This phase II study is evaluating how safe and effective a targeted therapy (imgatuzumab) is in people with advanced cutaneous squamous cell carcinoma.
This trial is treating patients with advanced cutaneous squamous cell carcinoma.
This is a systemic therapy trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Phase 2 Study of Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma (I-PACE)
Eligible participants in this trial will receive Imgatuzumab as monotherapy. Imgatuzumab will be administered as an intravenous infusion on Day 1 and Day 8 of the first 21-day cycle, and on Day 1 of each subsequent 14-day cycle.
Not Recruiting Hospitals Read More